Does the world's bestselling asthma drug sometimes kill the patients it is supposed to help? Frank A. Dittig was recovering from a nasty bout of pneumonia in the spring of 2004 when he developed a ...
GlaxoSmithKline plc (GSK) today announced results from the 'LABA' (long acting beta 2-agonist) safety study, AUSTRI(SAS115359). The study compared Advair ® Diskus ®, a combination of the LABA, ...
Advair is one of the biggest blockbusters in pharmaceutical history. The asthma drug has generated more than $80 billion in global revenues for its maker, GlaxoSmithKline, since its U.S. approval in ...
LONDON (Reuters) - GlaxoSmithKline is likely to escape generic competition to its blockbuster lung drug Advair in the United States this year, after a second application for a cut-price equivalent ...
LONDON (Reuters) - GlaxoSmithKline (GSK.L) received a boost on Monday from a decision by Express Scripts (ESRX.O), the largest U.S. pharmacy benefit manager, to reinstate its top-selling lung drug ...
If Mylan’s aggressive pricing for its generic Advair product sounds familiar, that’s because it is. The knockoffs giant set the list price for Wixela Inhub, its copy of GlaxoSmithKline’s respiratory ...
Lannett has submitted an ANDA to the Food and Drug Administration for its strategic partner, Respirant's fluticasone propionate and salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) ...
Lannett has entered into an exclusive U.S. distribution agreement for Respirent’s generic Advair Diskus (fluticasone propionate – salmeterol xinafoate powder inhaler), which is still pending approval ...
April 20 (Reuters) - Teva Pharmaceutical Industries Ltd on Thursday launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline's best-selling Advair. Teva, which won U.S.
LONDON, March 30 (Reuters) - GlaxoSmithKline's new CEO Emma Walmsley, who takes over on April 1, has won a short-term reprieve from the threat of generic Advair with a delay in U.S. approval for Mylan ...
GlaxoSmithKline has confirmed it will face a challenging 2019 as generics of its big-selling Advair drug finally reach the US, as it continues the transformation of its business. The FDA approved the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results